Medicinova Announced That Principal Investigator Presented The Results Of The Phase 2B Trial Of Mn-166 (Ibudilast) In Alcohol Use Disorder At The 46th Annual Research Society On Alcoholism Scientific Meeting
Portfolio Pulse from Benzinga Newsdesk
Medicinova announced the results of the Phase 2B trial of MN-166 (Ibudilast) in Alcohol Use Disorder at the 46th Annual Research Society on Alcoholism Scientific Meeting. The results of the trial were presented by the principal investigator.
June 29, 2023 | 10:07 am
News sentiment analysis
Sort by:
Ascending
POSITIVE IMPACT
Medicinova's announcement of the Phase 2B trial results of MN-166 could potentially impact the company's stock.
The announcement of positive clinical trial results often leads to an increase in the company's stock price as it indicates progress in the company's product pipeline. However, the actual impact will depend on the details of the results and the market's perception of them.
CONFIDENCE 70
IMPORTANCE 80
RELEVANCE 100